| Literature DB >> 21168742 |
R F Saidi1, S A Shah, A P Rawson, St Grossman, B Piperdi, A Bozorgzadeh.
Abstract
Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21168742 DOI： 10.1016/j.transproceed.2010.09.147
Source DB: PubMed Journal: Transplant Proc ISSN： 0041-1345 Impact factor: 1.066